Le Lézard

Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

Gilead Sciences, Inc. today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who are virologically ...

GILD's Investigational Regimen for HIV Treatment Meets Primary Goal

Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex ...
MPR

Single-Tablet Bictegravir/Lenacapavir Noninferior to Multi-Pill HIV-1 Regimens

Topline results were announced from a phase 3 trial evaluating bictegravir 75mg/lenacapavir 50mg (BIC/LEN), an investigational single-tablet regimen for the treatment of HIV-1.

Gilead stock rises after positive HIV treatment trial results

Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) stock rose 2.7% on Thursday after the company announced positive topline ...
TipRanks on MSN

Gilead announces ARTISTRY-1 trial meets primary endpoint

Gilead (GILD) announced topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with ...